@misc{oai:repo.qst.go.jp:00068005,
 author = {Ishikawa, Hiroyuki and Yoshikawa, Kyosan and Sagou, Kenji and Tamura, Katsumi and Koga, Masahisa and Kandatsu, Susumu and Mizoe, Junetsu and Tanada, Shuji and Tsujii, Hirohiko and et.al and 石川 博之 and 吉川 京燦 and 佐合 賢治 and 田村 克巳 and 古賀 雅久 and 神立 進 and 溝江 純悦 and 棚田 修二 and 辻井 博彦},
 month = {Jun},
 note = {Objectives:Malignant melanoma in head and neck region accounts for 30 to 56 percent of all malignant melanoma in Japan,and nasal malignant melanoma is especially very rare among them. The carbon ion radiotherapy (CIRT) has been introduced in our institute,and we have treated the nasal malignant melanoma using carbon ion beam. We evaluated whether C-11 methionine (MET) uptake and its change after CIRT were the early survival factors in patients with nasal malignant melanoma. 
Methods:MET-PET was prospectively performed in 28 patients with nasal malignant melanoma before CIRT, and 25 patients among them were also received MET-PET after CIRT. Patients were followed for 4.8 to 35.3 months (mean:16.2 months) after CIRT. Tumor MET uptake was measured with the semiquantitative tumor-to-muscle ratio (TMR).The MET uptake in the tumor and the result of short-term prognosis were entered into Kaplan-Meier analysis. The relationship between the change of MET uptake after CIRT and the result of local control rate, CR (complete remission) or PR (partial response) group and SD (stable disease) group, was also analyzed.
Results:The overall median survival time was 12.9 months. Patients with a baseline TMR of < 10.7 had a significant better survival than patients with a baseline TMR > 10.7 (2-year survival rate:68.8% versus 31.2%, P=0.038). Patients with a post CIRT TMR < 7.0 had a better survival than that with a post CIRT TMR > 7.0(2-year survival rate:79.0% versus 21.0%,  P=0.043). No statistically significant difference of survival rate was observed between any two patient groups of posttherapeutic MET uptake change. A significant higher local control rate was observed in patients with posttherapeutic MET uptake change of > 30% than patients in lower change group (2-yaer local control rate:72.5% versus 27.5%, P=0.018). 
Conclusions:MET uptake, as measured by either baseline or post CIRT TMR was an independent predictor of survival in patients with nasal malignant melanoma treated by carbon ion radiotherapy, while posttherapeutic MET uptake change might have potential value for predicting local control., Society of nuclear medicine's 51st. annual meeting},
 title = {C-11 METHIONINE POSITRON EMISSION TOMOGRAPHY AND SURVIVAL IN PATIENTS WITH NASAL MALIGNANT MELANOMA TREATED BY CARBON ION RADIOTHERAPY.},
 year = {2004}
}